Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Comparison of cognitive functional therapy and movement system impairment treatment in chronic low back pain patients: a randomized controlled trial
Ahmad SNS, Letafatkar A, Brewer BW, Sharifnezhad A
BMC Musculoskeletal Disorders 2023 Aug 29;24(684):Epub
clinical trial
8/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: Yes; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: Yes; Intention-to-treat analysis: Yes; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

BACKGROUND: This study aimed to compare the effects of cognitive functional therapy (CFT) and movement system impairment (MSI)-based treatment on pain intensity, disability, Kinesiophobia, and gait kinetics in patients with chronic non-specific low back pain (CNSLBP). METHODS: In a single-blind randomized clinical trial, we randomly assigned 91 patients with CNSLBP into CFT (n = 45) and MSI-based treatment (n = 46) groups. An 8-week training intervention was given to both groups. The researchers measured the primary outcome, which was pain intensity (Numeric rating scale), and the secondary outcomes, including disability (Oswestry disability index), Kinesiophobia (Tampa Kinesiophobia Scale), and vertical ground reaction force (VGRF) parameters at self-selected and faster speed (Force distributor treadmill). We evaluated patients at baseline, at the end of the 8-week intervention (post-treatment), and six months after the first treatment. We used mixed-model ANOVA to evaluate the effects of the interaction between time (baseline versus post-treatment versus six-month follow-up) and group (CFT versus MSI-based treatment) on each measure. RESULTS: CFT showed superiority over MSI-based treatment in reducing pain intensity (p < 0.001, Effect size (ES) = 2.41), ODI (p < 0.001, ES = 2.15), and Kinesiophobia (p < 0.001, ES = 2.47) at eight weeks. The CFT also produced greater improvement in VGRF parameters, at both self-selected (FPF (p < 0.001, ES = 3), SPF (p < 0.001, ES = 0.5), MSF (p < 0.001, ES = 0.67), WAR (p < 0.001, ES = 1.53), POR (p < 0.001, ES = 0.8)), and faster speed, FPF (p < 0.001, ES = 1.33, MSF (p < 0.001, ES = 0.57), WAR (p < 0.001, ES = 0.67), POR (p < 0.001, ES = 2.91)) than the MSI, except SPF (p < 0.001, ES = 0.0) at eight weeks. CONCLUSION: This study suggests that the CFT is associated with better results in clinical and cognitive characteristics than the MSI-based treatment for CNSLBP, and the researchers maintained the treatment effects at six-month follow-up. Also, This study achieved better improvements in gait kinetics in CFT. CTF seems to be an appropriate and applicable treatment in clinical setting. TRIAL REGISTRATION: The researchers retrospectively registered the trial 10/11/2022, at https://www.umin.ac.jp/ with identifier number (UMIN000047455).

Full text (sometimes free) may be available at these link(s):      help